NCT04199598 - Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 28, 2020

Primary Completion Date

April 3, 2020

Study Completion Date

April 3, 2020

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Abediterol (2.4 μg)

2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser

DRUG

Abediterol (4.8 μg)

4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser

DRUG

Abediterol (2.4 μg)

2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser

DRUG

Abediterol (2.5 μg)

2.5 μg (nominal dose) abediterol via DPI, reference

Trial Locations (1)

Research Site, Berlin